6,678 trials
Sciatica · Back Pain
Primary: To Demonstrate a Statistically Significant Difference in the Relief of Back Pain Between Both Treatment Groups. The Endpoint Will be the Difference Between Baseline and…
Knee Pain After Total Knee Arthroplasty · Osteoarthritis Pain
Primary: Change in Pain Visual Analogue Scale(VAS). — 44 units on a scale
Neurogenic Bladder Dysfunction Nos
Primary: Quality of Life (0-100 Point) — 76.8; 59.8 units on a scale
Insomnia · Spinal Cord Injury · Tetraplegia
Primary: Amount of Wakefulness After Sleep Onset (WASO) — 72.3; 76.5 Minutes — p=0.70
Dyslipidemias
Primary: Comparison Between XueZhiKang and Simvastatin on Fatigue Scores — 19.58; 21.58; 19.26; 19.33 units on a scale
Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Week 12 — -6.0 mmHg
Surgical Site Infection
Primary: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure — 0; 5 participants
Heart Failure
Primary: Percent of Patients Achieving a Desired Steady-state Serum Digoxin Concentration Between 0.5 - 0.9ng/ml — 38.5; 34.8 percentage of participants
General Anesthesia · Propofol Target-controlled Infusion · Thoracic Epidural Anesthesia
Primary: Propofol Effect-site Concentration — 1.76; 1.14; 1.09; 1.04 ug/ml
Dupuytren's Disease
Primary: The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation. — 482 mm^3 — p=<0.0013
Social Anxiety Disorder
Primary: Liebowitz Social Anxiety Scale (LSAS) — 39.19; 42.44 units on a scale
Alzheimer's Dementia
Primary: Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method — 81.70; 80.40; 84.60; 81.33 Bq/Bq (no unit) — p=0.14
Pompe Disease · Glycogen Storage Disease Type II
Primary: Change From Baseline in Number of Patients With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study — 2; 2…
Renal Function and Chronic Allograft Vasculopathy
Primary: Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation — 79.8; 61.5 mGFR ml/min
Intercritical Gout
Primary: Number of Gout Flares Per Participant From Day 1 to Week 16 — 1.1; 0.3 gout flares